Glioblastoma Multiforme (GBM) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Summary
Global 麻豆原创s Direct's latest Pharmaceutical and Healthcare disease pipeline guide Glioblastoma Multiforme (GBM) - Drugs In Development, 2022, provides an overview of the Glioblastoma Multiforme (GBM) (Oncology) pipeline landscape.
Glioblastoma also known as glioblastoma multiforme is a fast-growing glioma that develops from star-shaped glial cells that support the health of the nerve cells within the brain. Symptoms include headaches, blurred vision, nausea, vomiting, memory loss, speech difficulty, muscle weakness and loss of appetite. Risk factors include gender (male) and age. Treatment includes surgery, radiation therapy and chemotherapy.
Report Highlights
Global 麻豆原创s Direct's Pharmaceutical and Healthcare latest pipeline guide Glioblastoma Multiforme (GBM) - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Glioblastoma Multiforme (GBM) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Glioblastoma Multiforme (GBM) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Glioblastoma Multiforme (GBM) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 15, 103, 105, 5, 16, 246, 61 and 3 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages comprises 1, 10, 14, 1, 58 and 10 molecules, respectively.
Glioblastoma Multiforme (GBM) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global 麻豆原创s Direct鈥檚 proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Glioblastoma Multiforme (GBM) (Oncology).
- The pipeline guide reviews pipeline therapeutics for Glioblastoma Multiforme (GBM) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Glioblastoma Multiforme (GBM) (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Glioblastoma Multiforme (GBM) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Glioblastoma Multiforme (GBM) (Oncology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Glioblastoma Multiforme (GBM) (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it鈥檚 most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Glioblastoma Multiforme (GBM) (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
List of Tables
List of Figures
Introduction
Global 麻豆原创s Direct Report Coverage
Glioblastoma Multiforme (GBM) - Overview
Glioblastoma Multiforme (GBM) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Glioblastoma Multiforme (GBM) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Glioblastoma Multiforme (GBM) - Companies Involved in Therapeutics Development
Glioblastoma Multiforme (GBM) - Drug Profiles
Glioblastoma Multiforme (GBM) - Dormant Projects
Glioblastoma Multiforme (GBM) - Discontinued Products
Glioblastoma Multiforme (GBM) - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
List of Tables
Number of Products under Development for Glioblastoma Multiforme (GBM), 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Glioblastoma Multiforme (GBM) - Dormant Projects, 2022
Glioblastoma Multiforme (GBM) - Discontinued Products, 2022
List of Figures
List of Figures
Number of Products under Development for Glioblastoma Multiforme (GBM), 2022
Number of Products under Development by Companies, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022
1st Bio Therapeutics Inc
4D Pharma Plc
A. Menarini Industrie Farmaceutiche Riunite Srl
Aadi Bioscience Inc
AB Pharma Ltd
AbbVie Inc
Ability Pharmaceuticals SL
ABM Therapeutics Inc
Accendatech Co Ltd
Acomhal Research Inc
Actuate Therapeutics Inc
Acura Nanomedicine Inc
ADCendo ApS
Adlai Nortye Biopharma Co Ltd
Advanced Accelerator Applications SA
Advenchen Laboratories LLC
Adze Biotechnology Inc
Aettis Inc
Affimed GmbH
Agenus Inc
AiVita Biomedical Inc
Akeso Inc
Alaunos Therapeutics Inc
Alphageneron-Pharmaceuticals Inc
Alterity Therapeutics Ltd
Amal Therapeutics SA
Amasa Technologies Inc
Ambrx Biopharma Inc
Anagenics Ltd
Annji Pharmaceutical Co Ltd
Apac Biotech Pvt Ltd
Apexigen Inc
APIM Therapeutics AS
Apmonia Therapeutics SAS
Apogenix AG
Apollomics Inc
Aptamer Sciences Inc
Arcus Biosciences Inc
Argonaut Therapeutics Ltd
Arrien Pharmaceuticals LLC
Arrogene Inc
Aslan Pharmaceuticals Ltd
Astellas Pharma Inc
Astex Pharmaceuticals Inc
AstraZeneca Plc
Athenex Inc
Aucentra Therapeutics Pty Ltd
AUM Biosciences Pte Ltd
Avalia Immunotherapies Ltd
Avesthagen Ltd
Aveta Biomics Inc
Baobab AiBIO Co Ltd
Bayer AG
Beactica Therapeutics AB
BeiGene Ltd
Beijing Immunochina Pharmaceuticals Co Ltd
Bellicum Pharmaceuticals Inc
BenevolentAI Ltd
Berg LLC
BerGenBio ASA
Beta Pharma Inc
Bexion Pharmaceuticals LLC
BeyondBio Inc
Bicara Therapeutics Inc
Bio-Path Holdings Inc
Bio-Thera Solutions Ltd
Bioasis Technologies Inc
BioEclipse Therapeutics Inc
BioIntegrator
BioNTech SE
Biorchestra Co Ltd
Biovista Inc
BioXpress Therapeutics SA
Black Diamond Therapeutics Inc
Boehringer Ingelheim International GmbH
Boryung ViGenCell Inc
BoYuan RunSheng Pharma Hangzhou Co Ltd
Breakpoint Therapeutics GmbH
Bristol-Myers Squibb Co
Candel Therapeutics Inc
Cantex Pharmaceuticals Inc
Carina Biotech Pty Ltd
CARsgen Therapeutics Ltd
Cell Medicine Cooperation
Cellatoz Therapeutics Inc
CellCure
Celldex Therapeutics Inc
Cellestia Biotech AG
Cellis AG
Cellivery Therapeutics Inc
Cellworks Group Inc
Celros Biotech Co Ltd
Century Therapeutics Inc
Chemestmed OU
Chengdu Jinrui Foundation Biotechnology Co Ltd
Chengdu Kanghong Pharmaceuticals Group Co Ltd
Chimeric Therapeutics Ltd
Chimerix Inc
Clarity Pharmaceuticals Ltd
Cloaked Therapeutics LLC
Clonz Biotech Pvt Ltd
CNS Pharmaceuticals Inc
Codiak BioSciences Inc
Cothera Bioscience Pty Ltd
Cotinga Pharmaceuticals Inc
Curative Biotechnology Inc
CureLab Oncology Inc
Curevac NV
Curigin Co Ltd
Curtana Pharmaceuticals Inc
Cynata Therapeutics Ltd
Cytix Inc
Cytodyn Inc
Cytonus Therapeutics Inc
Cytovia Holdings Inc
Daiichi Sankyo Co Ltd
Dalriada Therapeutics Inc
DEKK-TEC Inc
Denovo Biopharma LLC
DevaCell Inc
Diakonos Research Ltd
Diverse Biotech Inc
Divide and Conquer Ltd
DNAtrix Inc
DynamiCure Biotechnology LLC
Edison Oncology Holding Corp
EirGenix Inc
Eisai Co Ltd
Eli Lilly and Co
Elicera Therapeutics AB
Elpis Biopharmaceuticals Corp
ENB Therapeutics LLC
EnduRx Pharmaceuticals Inc
Enochian Biosciences Inc
EntreChem SL
Enveric Biosciences Inc
EpicentRx Inc
EpiDrugs Discovery
Epigene Therapeutics Inc
ERC Belgium SA
ERYTECH Pharma SA
Etirarx LLC
Eutilex Co Ltd
Ever Supreme Bio Technology Co Ltd
Everfront Biotech Inc
Evgen Pharma Plc
Exopharm Ltd
F. Hoffmann-La Roche Ltd
Falcon Therapeutics Inc
Felicitex Therapeutics Inc
Flag Therapeutics Inc
Flavocure Biotech LLC
Fore Biotherapeutics Inc
Fujifilm Holdings Corp
Galapagos NV
Gan & Lee Pharmaceuticals Co Ltd
Gedeon Richter Plc
Geneius Biotechnology Inc
Genenta Science SpA
Genentech USA Inc
Geneos Therapeutics Inc
Genexine Inc
Genisphere LLC
Genomefrontier Therapeutics Inc
Genor BioPharma Co Ltd
Genoscience Pharma
Gilead Sciences Inc
GlioCure SAS
Glycostem Therapeutics BV
GlyTherix Ltd
GSK plc
Guangdong Zhongsheng Pharmaceutical Co Ltd
Guangxi Hebabiz Pharmaceutical Co Ltd
HaimBio Ltd
Hamlet Pharma AB
Hanmi Pharmaceuticals Co Ltd
Harbin Gloria Pharmaceuticals Co Ltd
Hebei Senlang Biotechnology Co Ltd
Hemispherian AS
HOX Therapeutics Ltd
Humanigen Inc
Hunan Siweikang Therapeutics Ltd
Hutchison MediPharma Ltd
i2 Pharmaceuticals Inc
Ibex Biosciences LLC
Immatics NV
Immix BioPharma Inc
ImmPACT Bio USA Inc
ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd
Immunitor Inc
ImmunityBio Inc
ImmunoAct Pvt Ltd
Immunomic Therapeutics Inc
Implicyte Inc
Imunon Inc
IMV Inc
Imvax Inc
IN8bio Inc
Incyte Corp
Infinity Pharmaceuticals Inc
Ingenew Pharmaceuticals Inc
Inovio Pharmaceuticals Inc
Inspirna Inc
Instituto Biomar SA
IntelliStem Technologies Inc
Intensity Therapeutics Inc
InterLeukin Combinatorial Therapies Inc
InteRNA Technologies BV
Invectys SA
Isarna Therapeutics GmbH
Istari Oncology Inc
ITM Isotope Technologies Munich SE
J Ints Bio Co Ltd
JenKem Technology Co Ltd
Jiangsu Hengrui Medicine Co Ltd
Johnson & Johnson
Jubilant Therapeutics Inc
JW CreaGene Co Ltd
Kalgene Pharmaceuticals Inc
Kancera AB
Kartos Therapeutics Inc
Karus Therapeutics Ltd
Karyo Biologics LLC
Karyopharm Therapeutics Inc
Kazia Therapeutics Ltd
Kidswell Bio Corp
Kintara Therapeutics Inc
Komipharm International Co Ltd
Kringle Pharma Inc
Lacerta Therapeutics Inc
Laminar Pharmaceuticals SA
Lantern Pharma Inc
Lauren Sciences LLC
LeadInvent Pharma Inc
Legend Biotech Corp
Lentigen Technology Inc
Liangjiang Medicine Co Ltd
Lin Bioscience Inc
Luminus Biosciences Inc
Lumos Pharma Inc
Luye Pharma Group Ltd
MacroGenics Inc
MAIA Biotechnology Inc
Matrix Biomed Inc
Medesis Pharma SA
Medical Guidance Systems LLC
Medicenna Therapeutics Corp
Medicon Pharmaceuticals Inc
Medisun Precision Medicine Ltd
MedPacto Inc
Mepsgene Co Ltd
Mercaptor Discoveries Inc
Merck & Co Inc
Merck KGaA
Meryx Inc
Metis Precision Medicine
MetVital Inc
MGC Pharmaceuticals Ltd
Midatech Pharma Plc
Millennium Pharmaceuticals Inc
MimiVax LLC
Mina Therapeutics Ltd
MiReven Pty Ltd
Molecular Targeting Technologies Inc
Moleculin Biotech Inc
Mustang Bio Inc
Mycenax Biotech Inc
Myeloid Therapeutics Inc
Myosin Therapeutics Inc
Myrio Therapeutics Pty Ltd
Nanjing Aimeifei Biomedical Technology Co Ltd
Nanjing CART Medical Technology Co Ltd
Nanjing KAEDI Biotech Inc
Nanocan Therapeutics Corp
NanoCarrier Co Ltd
Nanomerics Ltd
NanoPharmaceuticals LLC
Nascent Biotech Inc
NatureWise Biotech & Medicals Corp
NeoTX Therapeutics Ltd
Neuropore Therapies Inc
NewG Lab Pharma Inc
NGM Biopharmaceuticals Inc
NH TherAguix SAS
Northlake International LLC
Northwest Biotherapeutics Inc
Nostrum Biodiscovery SL
Novartis AG
Noxopharm Ltd
Nuvalent Inc
NuvOx Pharma LLC
Nyrada Inc
Oblato Inc
Ocean Biomedical Inc
OGD2 Pharma SAS
Oleolive LLC
Omniox Inc
Oncodesign SA
Oncolytics Biotech Inc
Onconova Therapeutics Inc
OncoResponse Inc
Oncorus Inc
OncoRx Pharmaceuticals Inc
Oncotelic Therapeutics Inc
Oncoteq AG
OncXerna Therapeutics Inc
OneChain Immunotherapeutics
Ono Pharmaceutical Co Ltd
Origenis GmbH
Orphelia Pharma SAS
Ossianix Inc
Otsuka Pharmaceutical Co Ltd
Ovensa Inc
Palisades Therapeutics
Parabon NanoLabs Inc
Pascal Biosciences Inc
Patrys Ltd
PENAO Pty Ltd
Peptomyc SL
Pfizer Inc
Phanes Therapeutics Inc
Pharma Mar SA
PharmAbcine Inc
PharmCADD Co Ltd
Philogen SpA
Phoenix Biotechnology Inc
Phost'IN SAS
Photolitec LLC
Photonamic GmbH & Co KG
Pinotbio Inc
Plex Pharmaceuticals Inc
Plexxikon Inc
Polaris Pharmaceuticals Inc
PolyPid Ltd
Praesidia Biotherapeutics Inc
Prelude Therapeutics Inc
Prescient Therapeutics Ltd
Preveceutical Medical Inc
Primevax Immuno Oncology Inc
PTC Therapeutics Inc
Puma Biotechnology Inc
QED Therapeutics Inc
Quadriga BioSciences Inc
Qualigen Therapeutics Inc
R-Pharm
Radiopharm Theranostics Ltd
Refuge Biotechnologies Inc
Regeneron Pharmaceuticals Inc
Reglagene Holding Inc
Regulus Therapeutics Inc
ReNeuron Group Plc
Ridgeline Therapeutics LLC
Rottapharm Biotech Srl
Rznomics Inc
Safe Save Medical Cell Sciences & Technology Co Ltd
Sagimet Biosciences Inc
Salarius Pharmaceuticals Inc
Sano Chemicals Inc
Sanofi
Sapience Therapeutics Inc
Sentinel Oncology Ltd
Serb SAS
Shanghai Escugen Biotechnology Co Ltd
Shanghai Henlius Biotech Inc
Shanghai HyaMab Biotech Co Ltd
Shanghai Novamab Biopharmaceuticals Co Ltd
Shanghai YaKe Biotechnology Co Ltd
Shenzhen BinDeBio Ltd
Shenzhen Zhenxing Pharmaceutical Technology
Shuttle Pharmaceuticals Inc
SideROS
SignPath Pharma Inc
Silenseed Ltd
Singh Biotechnology LLC
SixFold Bioscience Ltd
SK Life Science Inc
SL Bigen Co Ltd
SL VaxiGen Inc
Spectrum Pharmaceuticals Inc
Speer Medical Technologies LLC
STAT3 Therapeutics Inc
StemGen SpA
StemVax LLC
Suntec Medical (Taiwan) Inc
Susavion Biosciences Inc
Suzhou JiSheng Pharmaceutical Co Ltd
Suzhou Stainwei Biotech Inc
Synactix Pharmaceuticals Inc
Synchronicity Pharma Inc
Synergys Biotherapeutics Inc
SyntheX Inc
Tactical Therapeutics Inc
TAE Life Sciences LLC
Taiho Oncology Inc
Tango Therapeutics Inc
Targinta AB
TargTex SA
TC BioPharm Ltd
Telo Therapeutics Inc
Telomium SAS
The Palo Alto Research Center
TheraBiologics Inc
TheraBioPharma Inc
Theralase Technologies Inc
Therapeia GmbH & Co KG
Titan Pharmaceuticals Inc
TME Pharma AG
Tmunity Therapeutics Inc
Transcode听Therapeutics Inc
Transtarget Inc
Trevarx Biomedical Inc
Triterpenoid Therapeutics Inc
Turning Point Therapeutics Inc
TVAX Biomedical Inc
Tyme Inc
U-Cell Therapeutics Pte Ltd
Up Therapeutics Inc
UTC Therapeutics Inc
Vault Pharma Inc
VBI Vaccines Inc
VCN Biosciences SL
Vect-Horus SAS
Verismo Therapeutics
Vigeo Therapeutics Inc
Vivace Therapeutics Inc
Voronoi Group
Vyro Bio Inc
Wayshine Biopharma Inc
Wigen Biomedicine Technology (Shanghai) Co Ltd
WindMIL Therapeutics Inc
WPD Pharmaceuticals Inc
Wuhan Binhui Biotechnology Co Ltd
X4 Pharmaceuticals Inc
Xequel Bio Inc
Xi'An Yufan Biotechnology Co Ltd
Xonovo Inc
Yooyoung Pharm Co Ltd
Yuhan Corp
Yumanity Therapeutics Inc
Zata Pharmaceuticals Inc
Zentalis Pharmaceuticals Inc
ZhongSheng BioTech Inc
Zumutor Biologics Inc
听
听
*If Applicable.